Clinical Trials
Participate in groundbreaking research studies that help develop new treatments and medications for various health conditions.
Filter by study
ATLAS
Who is this for?
Those with uncontrolled moderate to severe asthma
Study:
This study looks at the drug dupilumab. It aims to evaluate the long term effects (if any) of dupilumab on preventing/slowing the rate of predicted lung function decline.
BRISTOTE
Who is this for?
Those with uncontrolled eosinophilic asthma despite inhaler use
Study:
This study looks at the drug benralizumab. It aims to see how combining benralizumab with inhaled medium dose asthma medication compares to only using high dose inhaled asthma medication on improving asthma symptoms.
ENDURA
Who is this for?
Those with symptomatic COPD (have had ≥2 moderate OR ≥ 1 severe exacerbations in the past year)
Study:
This study aims to evaluate the efficacy and safety of the drug depemokimab in addition to existing triple therapy inhalers in participants with uncontrolled moderate to severe COPD.
FeNO in Asthma Pilot
Who is this for?
Those who are suspected to have asthma, but have normal spirometry results
Study:
This PI-initiated study observes if the immediate measurement of nitric oxide will determine those patients for whom challenge testing should be expedited and those for whom such testing can be deferred.
LAKE
Who is this for?
Those with refractory or unexplained chronic cough (cough ≥ 8 weeks)
Study:
This clinical trial evaluats the efficacy and safety of extended-release nalbuphine tablets in adults with refractory chronic cough.
LILLY GZMR
Who is this for?
Those with uncontrolled asthma with a BMI over 22
Study:
This study looks at the GLP-1/GIP agonist, Brenipatide. It evaluates the effectiveness of different doses of Brenipatide to manage asthma symptoms.
PERSEPHONE
Who is this for?
Those with symptomatic COPD (have had ≥2 moderate OR ≥ 1 severe exacerbations in the past year)
Study:
This clinical trial evaluates the safety and efficacy of the investigational medication lunsekimig in adults with eosinophilic chronic COPD whose disease remains inadequately controlled despite standard treatment.
REALITI-C
Who is this for?
Those using mepolizumab for the treatment of their COPD
Study:
This study looks to observe the effectiveness of mepolizumab (Nucala) in managing COPD symptoms. (This drug has already been approved by Health Canada).
REDWOOD-LIVER
Who is this for?
Alpha-1 antitrypsin deficiency patients with a ZZ genotype and moderate-severe liver fibrosis
Study:
This study looks at the drug fazirsiran. It aims to observe the efficacy of the investigational drug compared to placebo at improving AATD induced liver fibrosis.
REDWOOD-LUNG
Who is this for?
Alpha-1 antitrypsin deficiency patients with a ZZ genotype and mild liver fibrosis
Study:
This study looks at the drug fazirsiran. It aims to observe the safety, tolerability and efficacy of the investigational drug. It will look at any effects on lung function and liver scarring.
Participating in a Clinical Trial
Benefits
- Access to new treatments before they're widely available
- Regular and careful medical attention from research staff
- Helping to advance medical knowledge
- Potential compensation for time and travel
Considerations
- Possible side effects or risks from experimental treatments
- Time commitment for appointments and procedures
- May require stopping current medications
- No guarantee the experimental treatment will work
Our Commitment
- Full disclosure of potential risks and benefits
- Comprehensive informed consent process
- Right to withdraw from the study at any time
- Ongoing monitoring of your health and safety
Interested in Participating?
If you're interested in participating in a clinical trial, please contact our research team for more information about current opportunities and the enrollment process.
Contact Our Research Team